Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Forecast: How Large Could The Market Become By 2030?
The market for human immunodeficiency virus (HIV) clinical trials has experienced robust expansion lately. Projections indicate substantial growth, increasing from $1.94 billion in 2025 to $2.11 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this historical growth trajectory include the significant global burden of HIV disease, the broadening scope of antiretroviral drug investigations, augmented financial backing from both public and private sectors for HIV research initiatives, enhancements in clinical research infrastructure, and favorable regulatory environments supporting the progression of HIV drug development.
The global market for Human Immunodeficiency Virus (HIV) clinical trials is poised for considerable expansion, projected to reach $2.97 billion by 2030, driven by an 8.9% compound annual growth rate. This anticipated growth is fueled by several key factors including the accelerating development of treatments aimed at curing and preventing HIV, the increasing implementation of adaptive clinical trial methodologies, a heightened emphasis on vaccine-related HIV research, the burgeoning application of artificial intelligence within the clinical research sphere, and a more pronounced concentration on evaluating the long-term safety and effectiveness of interventions. Furthermore, significant market trends expected to shape this period encompass the growing acceptance of decentralized clinical trial approaches, the expanded utilization of digital platforms for patient recruitment, an elevated focus on long-acting HIV therapeutic agents in ongoing trials, the greater incorporation of real-world evidence, and an improved application of data analytics for optimizing trial administration.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28244&type=smp
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Demand Drivers Creating New Revenue Opportunities
The expanding prevalence of Human Immunodeficiency Virus (HIV) diagnoses is anticipated to stimulate advancement within the HIV clinical trials sector. This condition, stemming from the HIV virus’s assault on the immune system, renders individuals more vulnerable to subsequent illnesses and can progress to Acquired Immunodeficiency Syndrome (AIDS). A significant factor contributing to the rise in HIV cases is a deficit in understanding how the virus is transmitted, which unfortunately leads to riskier conduct and delayed diagnostic assessments, thereby fostering the virus’s dissemination. Clinical trials for HIV play a crucial role in aiding affected individuals by evaluating novel pharmaceuticals, preventative measures like vaccines, and therapeutic approaches aimed at enhancing prevention, managing the virus with greater efficacy, and ultimately curbing its advancement and spread. Illustratively, as reported by the US-based Minority HIV/AIDS Fund (MHAF) in August 2024, an estimated 39.9 million people globally were contending with HIV in 2023, encompassing 38.6 million adults and 1.4 million children, a figure that reflects an upward trend from prior years. Consequently, the escalating rates of HIV infections are serving as a primary catalyst for the expansion of the HIV clinical trials market.
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Categorization By Product Type And Application
The human immunodeficiency viruses (hiv) clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical
2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations
5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies
2) By Phase II: Dose-Finding Studies, Efficacy Studies
3) By Phase III: Pivotal Trials, Comparative Efficacy Studies
4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies
5) By Preclinical: In Vitro Studies, Animal Studies
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Trends Driving Strategic Industry Expansion
Within the market for human immunodeficiency virus (HIV) clinical trials, key players are concentrating on pioneering advancements like injectable HIV preventatives, aiming to bolster the effectiveness of treatments and curb transmission. These injections are defined as extended-release medications given at intervals to preempt HIV acquisition in those at elevated risk by impeding the virus’s ability to initiate an infection. A notable development occurred in August 2025 when Gilead Sciences Inc., an American pharmaceutical entity, secured European Union authorization for Yeytuo (lenacapavir), a treatment for HIV. This medication, administered every six months, has demonstrated exceptional effectiveness in clinical studies, approaching 100% efficacy in preventing sexual transmission of HIV-1, thereby substantially diminishing the likelihood of contracting the virus. The prolonged duration of action offered by this injectable solution enhances patient compliance and ease of use, presenting a significant improvement over daily oral pre-exposure prophylaxis (PrEP) and addressing a critical need in HIV prevention efforts. Intended for both adults and adolescents who face a higher risk of infection, this innovation seeks to broaden accessibility and contribute to a global reduction in new HIV cases as part of broader preventative healthcare initiatives.
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Company Landscape And Strategic Competition
Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio
Access The Complete Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report:
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency viruses (hiv) clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
